Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

- 2008 revenue expected to grow to $160 million or more, up from $42

million in 2007 -

- First HGS product sales expected with delivery of ABthrax(TM) to

Strategic National Stockpile -

- First Albuferon(R) Phase 3 data expected late 2008 - - Enrollment completed in randomized Phase 2 trial of HGS-ETR1 in multiple

myeloma -

ROCKVILLE, Md., Feb. 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter and full year ended December 31, 2007, and provided highlights of recent progress toward commercialization.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"2007 was a year of execution for HGS, during which we delivered substantial progress toward the commercialization of our late-stage products. We are poised to achieve a number of major milestones in 2008 across our entire portfolio," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We expect our first product sales later this year when we begin to deliver ABthrax to the U.S. Strategic National Stockpile, and our cash position remains strong. We expect to have our first Phase 3 data for Albuferon late this year, and we will complete enrollment in the Phase 3 trials of LymphoStat-B(R) by fall 2008. We also believe it is possible that GSK will reach decisions in 2008 regarding whether to advance darapladib and Syncria to Phase 3 development."

FINANCIAL RESULTS: CASH POSITION REMAINS STRONG

HGS reported increased revenues of $41.9 million for the year ended December 31, 20
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
(Date:5/21/2013)... Md. , May 21, 2013  Synthetic Biologics, Inc. ... prevention and treatment of serious infectious diseases, announced today that ... the 2 nd Annual Marcum LLP MicroCap Conference on ... at the Grand Hyatt Hotel. Mr. Riley is ... A live webcast of Synthetic Biologics, presentation can be accessed ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Bed bugs ... according to My Cleaning Products, many turn to chemical-based pesticides ... of the health and environmental risks those solutions present, the ... with Bed Bug Bully instead. , According to My ... bugs as they used to be. It shared that the ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... ATHENS, Ohio Scientists have used new optical technologies ... principle usually would prohibit, according to a study published ... conducted experiments with high-powered lasers and quantum dots artificial ... devices for quantum communication and computing to learn ...
... MISSISSAUGA, ON, Jan. 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... operations for the,fiscal year ended November 30, 2007. ... unless otherwise noted., At November 30, 2007, ... with $30.4 million at November 30, 2006. The ...
... China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... outsourcing services is,proud to announce today that ... Li is named as one of the ... Entrepreneur China edition., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Scientists discover new method of observing interactions in nanoscale systems 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 2WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 3
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... Hypnosis can induce "synesthetic" experiences where one sense ... average brain, according to a new study in the ... the Association for Psychological Society. The findings ... do not necessarily have extra connections in their brain; ...
... infection is not a positive experience. However, by ... melanogaster with a Salmonella strain known for ... of Life Sciences at Arizona State University have ... with broad implications for understanding embryonic development, ...
... scientists say that a recent scientific study of a ... second, potentially more significant source of radon exposure for ... ore in the production arearesulted in relatively high levels ... More than half (56 percent) of the workers ...
Cached Biology News:Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2Making flies sick reveals new role for growth factors in immunity 2Making flies sick reveals new role for growth factors in immunity 3Making flies sick reveals new role for growth factors in immunity 4Major source of radon exposure overlooked at former Ohio uranium-processing plant 2Major source of radon exposure overlooked at former Ohio uranium-processing plant 3Major source of radon exposure overlooked at former Ohio uranium-processing plant 4
Request Info...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: